Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma

Leuk Lymphoma. 2019 Dec;60(14):3587-3589. doi: 10.1080/10428194.2019.1639169. Epub 2019 Jul 15.

Authors

Jun Watanabe¹, Manabu Natsumeda¹, Yu Kanemaru¹, Masayasu Okada¹, Makoto Oishi¹, Akiyoshi Kakita², Yukihiko Fujii¹

Affiliations

¹ Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
² Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.

PMID: 31305194
DOI: 10.1080/10428194.2019.1639169

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Biomarkers, Tumor / blood
Biomarkers, Tumor / cerebrospinal fluid
Biomarkers, Tumor / genetics*
Biomarkers, Tumor / urine
Body Fluids / chemistry*
Central Nervous System Neoplasms / blood
Central Nervous System Neoplasms / cerebrospinal fluid
Central Nervous System Neoplasms / diagnosis*
Central Nervous System Neoplasms / urine
Circulating Tumor DNA / blood
Circulating Tumor DNA / cerebrospinal fluid
Circulating Tumor DNA / genetics*
Circulating Tumor DNA / urine
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Lymphoma, Non-Hodgkin / blood
Lymphoma, Non-Hodgkin / cerebrospinal fluid
Lymphoma, Non-Hodgkin / diagnosis*
Lymphoma, Non-Hodgkin / urine
Male
Middle Aged
Myeloid Differentiation Factor 88 / genetics*
Neoplasm Recurrence, Local / blood
Neoplasm Recurrence, Local / cerebrospinal fluid
Neoplasm Recurrence, Local / diagnosis*
Neoplasm Recurrence, Local / urine
Prognosis

Substances

Biomarkers, Tumor
Circulating Tumor DNA
MYD88 protein, human
Myeloid Differentiation Factor 88